MIR93 (MicroRNA 93)

Furthermore, miR-93-5p was validated as a critical gene, with its disruption leading to significant reductions in GBM cell proliferation, migration, and invasion. The novel CRM signature enhances the prognostic landscape for patients with LGG, offering a new framework for evaluating immunotherapeutic efficacy.

Our findings suggest that miR-20a-5p plays an oncogenic role in luminal breast cancer by promoting EMT, while MALAT1 may contribute to disease progression through indirect regulatory mechanisms. Finally, MALAT1 and miR-20a-5p might serve as potential therapeutic and prognostic targets in LBC.

Our findings reveal that exosomal miR-93-5p from PC cells drives M2 macrophage polarization and disease progression through SOCS6 suppression and JAK2/STAT3 pathway activation. These results identify exosomal miR-93-5p as a promising therapeutic target and provide new avenues for developing innovative treatment strategies against PC.

Interestingly, we also found that medications such as prasterone, tazemetostat, isoxyl, gemcitabine, ponsegromab, scx-2023, and nicotinamide could potentially be used in combination with the identified miRNAs to target ferroptosis in CRC. To further validate the stability and reliability of the predicted protein-ligand interactions, molecular dynamics (MD) simulations and MM-PBSA analyses were performed on selected top-ranking complexes, which confirmed their stable and favorable binding and supported the robustness of our docking results. These findings suggest that targeting these miRNAs and their associated genes, along with using the identified drugs, could be a promising strategy for CRC treatment, leveraging the potential of ferroptosis-inducing therapies.

Kaplan-Meier survival analysis demonstrated that high expression of hsa-miR-15a (p=0.023) and hsa-miR-221 (p=0.048) significantly correlated with poorer overall survival, suggesting their potential prognostic values. Dysregulated expression of cell-cycle-related miRNAs, particularly hsa-miR-15a and hsa-miR-221, may contribute to CESC progression and serve as potential prognostic biomarkers.

RBC-derived miR-93-5p is associated with immune checkpoint activation, T-cell exhaustion, and poor clinical outcomes, suggesting impaired antitumor immunity. Targeting this axis may improve the efficacy of immunotherapy in lung cancer.

The prognostic relevance of VEGF-A in LSCC is region-dependent, with clinically meaningful value confined to tumor depth. Together with a high-risk three-miRNA signature, these findings delineate two molecular subgroups capturing most recurrences and may inform sampling strategies and risk stratification.

Pathway enrichment linked these deregulated miRNAs to key oncogenic networks, particularly PI3K/AKT/mTOR, Wnt/β-catenin, and EMT regulation, demonstrating conserved molecular mechanisms shared with human BC and highlighting their potential as biomarkers in CMTs. These findings provide insights into the molecular mechanisms of CMT adenocarcinoma and suggest the potential of miRNA-based biomarkers for the diagnosis and treatment of CMTs.

MiR-126-5p, miR-150-5p, miR-214-3p, and miR-452-5p all showed a decrease in expression at at least one timepoint following splenectomy. These miRNAs have been previously shown to have roles in angiogenesis and pathways known to be involved in the pathogenesis of hemangiosarcoma and may be prospective targets for a minimally invasive diagnostic panel for the presence of splenic hemangiosarcoma.

Evaluation of miRNAs commonly deregulated between the three groups showed 14 shared upregulated miRNAs (miR-429, miR-425-5p, miR-200c-3p, miR-200c-5p, miR-200b-3p, miR-200a-3p, miR-183-5p, miR-182-5p, miR-141-5p, miR-141-3p, miR-96-5p, miR-93-5p, miR-10a-5p, miR-10a-3p) with a progressive increase in expression levels, from ovarian EMS to TL and ultimately to ECOC. The identified miRNA expression profiles associated with the progression from ovarian EMS, TL and ECOC provide valuable insights into the molecular progression from benign to malignant lesions and could represent potential biomarkers for the early detection of ECOC.

If a mass is not hemangiosarcoma, owners may be more likely to proceed with surgery rather than euthanasia. Knowing that a mass is hemangiosarcoma will provide information to owners on the need for adjuvant therapy following surgery.